Boehringer Ingelheim Collaborates with Cure Genetics to Develop Next-Generation Liver-Targeted Gene Therapy
Shots:
- The companies collaborated to develop AAV vectors deploying Cure Genetics' VELP platform to develop next-generation gene therapies
- The focus of the pact is to provide new AAV serotypes for patients. The collaboration integrates Boehringer Ingelheim's experience in disease biology and gene therapy development with Cure Genetics' AAV expertise in library construction and in vivo AAV screening
- The VELP technology provides effective solutions in increasing the efficiency of novel AAV screening- further expanding the efforts in the area of gene therapy development
Ref: PRNewswire | Image: Boehringer Ingelheim
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com